Aurobindo Pharma USA Inc., a fully owned subsidiary of Aurobindo Pharma Limited, has entered into a Collaboration and License Agreement with a leading global pharmaceutical company on November 22, 2024. This agreement focuses on the development and commercialization of products in the respiratory therapeutic area.
Key Highlights:
- Agreement Details: A collaboration to co-develop and co-commercialize respiratory products over the next 3-5 years. The agreement includes shared costs, with Aurobindo contributing up to USD 90 million.
- Details Of Consideration Paid In Agreement: An upfront payment of USD 25 million is made by the partner. Both companies will equally share development costs, with a cap for Aurobindo at USD 90 million.
- Manufacturing & Marketing: Products will be manufactured at the partner’s facility, with both parties sharing marketing efforts. Aurobindo has the option for future technology transfer.
TOPICS:
Aurobindo Pharma